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Abstract
Amyotrophic lateral sclerosis (ALS) is a lethal disorder characterized by the gradual degeneration of motor neurons in the
cerebrospinal axis.Whetheruppermotor neuronhyperexcitability, which is a feature of ALS, provokes dysfunction of glutamate
metabolism and degeneration of lower motor neurons via an anterograde process is undetermined. To examinewhether early
changes in upper motor neuron activity occur in association with glutamatergic alterations, we performed whole-cell patch-
clamp recordings to analyze excitatory properties of Layer V cortical motor neurons and excitatory postsynaptic currents
(EPSCs) in presymptomatic G93Amice modeling familial ALS (fALS). We found that G93A Layer V pyramidal neurons exhibited
altered EPSC frequency and rheobase values indicative of their hyperexcitability status. Biocytin loading of these hyperexcitable
neurons revealed an expansion of their basal dendrite arborization. Moreover, we detected increased expression levels of the
vesicular glutamate transporter 2 in cortical Layer V of G93A mice. Altogether our data show that functional and structural
neuronal alterations associate with abnormal glutamatergic activity in motor cortex of presymptomatic G93A mice. These
abnormalities, expected to enhance glutamate release and to favor its accumulation in themotor cortex, provide strong support
for the view that upper motor neurons are involved early on in the pathogenesis of ALS.
Key words: excitatory neurotransmission, G93A mice, motor neuron hyperexcitability, neuronal morphology, vesicular
glutamate transporter
Introduction
Amyotrophic lateral sclerosis (ALS) is a lethal adult-onset neuro-
logical disease characterized by degeneration of the upper and
lower motor neurons (Wijesekera and Leigh 2009; Kiernan et al.
2011). The etiology of the disease remains elusive. Most cases
of ALS are sporadic (sALS), whereas familial ALS (fALS) constitu-
tes ∼5–10% of ALS cases and is usually inherited in an autosomal
dominant manner. Mutations in Cu/Zn superoxide dismutase
enzyme (SOD1) (Deng et al. 1993; Rosen et al. 1993; Moreira
et al. 2013) account for approximately ∼30% of fALS. Notably,
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the G93A transgenic mouse, which overexpresses the mutated
human sod1 gene in which glycine is substituted by alanine at
residue 93, shows clinical signs that closely mimic human ALS
and is the most characterized mouse model of ALS (Gurney
1994; Andersen 2006). In particular, G93Amice develop hindlimb
tremor and weakness at around 3months detected by locomotor
deficits, progressing to hyper-reflexia, paralysis, and premature
death after 4 months (Gurney 1994).
The pathophysiologicalmechanisms triggeringmotor neuron
vulnerability in ALS arises from a combination of mechanisms,
including environmental toxicity (Van Den Bosch et al. 2006;
Foran and Trotti 2009), mitochondrial dysfunction (Grosskreutz
et al. 2007), oxidative damage (Panov et al. 2011), aberrant protein
aggregation (Vance et al. 2009), deregulation of Ca2+ homeostasis
(Guatteo et al. 2007; Martorana et al. 2012), immune system defi-
ciency and neuroinflammation (Alexianu et al. 2001; Philips and
Robberecht 2011), and altered functionality of neuronal ionic
channels and excitability (Kuo et al. 2005; Zona et al. 2006; Pieri
et al. 2009; Carunchio et al. 2010; Vucic, Ziemann et al. 2013).
However,many of these abnormalities have been linked to an ex-
citotoxicity cascade that involves the glutamatergic neurotrans-
mitter system, with the accumulation of glutamate leading to an
excessive activation of glutamate receptors at the synaptic cleft
(Foran et al. 2011; Spalloni et al. 2011). Indeed, an enhanced glu-
tamate concentration in the cortex could have repercussions on
the expression of vesicular glutamate transporters (VGluTs),
which regulate the re-uptake of glutamate in their secretory vesi-
cles (Fremeau, Kam et al. 2004; Takamori 2006).
The “dying forward” hypothesis of ALS etiology posits that
motor neuron degeneration is the result of cortical cell hyperex-
citability, which induces modifications of glutamatergic activity
in upper motor neurons. This cascade subsequently promotes
anterior horn cell degeneration through an anterograde trans-
synaptic diffusion of excitotoxicity (Maekawa et al. 2004; Vucic
et al. 2011). Consistent with this hypothesis, transcranial mag-
netic stimulation studies have established that cortical hyperex-
citability is an early feature of sALS and even precedes the clinical
onset of fALS (Vucic et al. 2008). Remarkably, presymptomatic
upper motor neuron hyperexcitability has been reported in
G93A mice that model fALS and in wobbler mice that model
sALS (Stys 2005; Pieri et al. 2009; Carunchio et al. 2010; Nieto-Gon-
zalez et al. 2010). “Whether neuronal hyperexcitability is asso-
ciated with the cell alterations” and abnormal glutamate
concentration recognized as the cause of neuronal injury (Shob-
ha et al. 2007; Bogaert et al. 2010; Foran et al. 2011) remains un-
known. Here, we showed that motor cortex from 1-month-old
G93A mice exhibit hyperexcitability associated with neuronal
morphological changes and with abnormalities in glutamate
packaging that favor glutamate accumulation in the synaptic
terminals surrounding hyperexcitable neurons.
Materials and Methods
Animals
The experiments were performed using B6SJL-TgN (SOD1)2 Gur
mice that overexpressed wild-type human SOD1 (SOD1), B6SJL-
TgN (SOD1-G93A)1 Gur mice that over-overexpressed the G93A-
mutated human SOD1 (G93A) constructed by Gurney (1994),
and non-transgenic littermates as the control. Themicewere ori-
ginally obtained from Jackson Laboratories (Bar Harbor) and then
housed in our animal facilities. On postnatal day 21, the animals
were weaned, and a screening for the presence of the human
transgene was performed on the tail tips as previously described
(Beauchamp and Fridovich 1971; Pieri et al. 2003). Themice carry-
ing the transgene G93A, but not SOD1 or control mice, showed
signs of hind limb weakness and rapidly developed a paralysis
that resembled fALS both clinically and pathologically (Gurney
1994) at 4 months of age and died within 7–14 days.
Procedures involving the animals and their care were con-
ducted in strict accordance with the Policy on Ethics approved
by the Society for Neuroscience and with the European Commu-
nities Council Directive of 24 November 1986 (86/609/EEC) regard-
ing the care and use of animals for experimental procedures. All
experimentswere approved by the AnimalWelfare Committee of
the Italian Ministry of Health and the Regional Animal Ethics
Committee. Every effort was made to minimize the number of
animals used and their suffering.
Slice Preparation
control, G93A, and SOD1 male mice, aged 26 postnatal days (P26)
to P31, were anesthetized with halothane (Sigma–Aldrich) and
decapitated. The brains were removed and placed in cold artifi-
cial cerebrospinal fluid solution (ACSF) containing the following
(in m): 126 NaCl, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 MgSO4, 2
CaCl2, and 10 glucose, gassed with 95% O2–5% CO2 (pH 7.4,
300 mOsm). Coronal slices (275 μm) were obtained as previously
described (Carunchio et al. 2010) using a vibratome (Leica
VT1000S), covering approximately from 1.18 mm anterior to the
bregma (anteriorly) to −0.34 mm posterior to the bregma. Slices
were then incubated in the oxygenated ACSF, initially at 37°C
for 45 min and subsequently at room temperature (RT). The sin-
gle slice was then transferred to a recording chamber and sub-
merged in continuously flowing oxygenated ACSF (31°C, 2 mL/
min) for electrophysiological experiments. Some slices were uti-
lized for biochemical, molecular, and immunohistochemical
experiments.
Electrophysiology
Recordings were obtained from the deep part of Layer V pyram-
idal neurons of the primary motor cortex (M1), which were visu-
ally identified by their typical large soma size and the presence of
a thick apical dendrite oriented toward the pial surface (Stuart
et al. 1993) using an upright infrared microscope (Axioskop 2
FS), a 40× water immersion objective (Achroplan), and a CCD
camera (Cool Snap, Photometrics). Only neurons with a typical
pyramidal-shaped soma, regular-spiking, a membrane resist-
ance lower than 100 MΩ, and a membrane capacitance in the
range of 75–125 pF, corresponding to a diameter of 16–21 µm for
all experimental groups (Oswald et al. 2013; Suter et al. 2013),
were considered in this study. Neurons with electrophysiological
properties different from those typical of cortico-spinal motor
neurons have been rejected.
For the electrophysiological whole-cell recordings, borosili-
cate glass pipettes (outside diameter 1.5 mm; tip resistance
3–4 MΩ) were used. In order to morphologically identify the
recorded cells, some neurons were filled with 2% biocytin
(Sigma–Aldrich) through the recording pipette.
The passive membrane properties and the pattern of repeti-
tive firing were examined in the cortical motor neurons using a
current-clamp configuration. The pipettes were filled with an
intracellular solution containing (in m): 145 KGlu, 1 EGTA, 0.1
CaCl2, 10 HEPES, 2 MgCl2 and 2 Mg-ATP (pH 7.3, 300 mOsm). The
restingmembrane potential wasmeasured immediately after es-
tablishing the whole-cell recording configuration. Various inten-
sities of hyperpolarizing rectangular current pulses of 500-ms
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duration were used to determine the basic electrophysiological
properties. The membrane resistance of the cell was calculated
as the slope of the linear fit to the I–V relationship for currents be-
tween −60/+40 pA. The time constant of the membrane (τ mem-
brane) was calculated on the membrane potential variation in
response to a−100 pAhyperpolarizing current, fitted to the single
exponential function:
Vm ¼ Vr þ ðVf  VrÞð1 et=τ Þ;
where Vm is themembrane potential, Vr is the restingmembrane
potential, Vf is the final value of the membrane potential, t is the
time, and τ is the membrane time constant.
The action potential (AP) firing was recorded using 1-s de-
polarizing current steps (+20/+100-pA, 20-pA steps). For each
neuron, the firing frequencywas plotted against the injected cur-
rents (F–I relationship), and the gain value was calculated as the
slope of the linear fitting.
Rheobase is a measure of membrane excitability and was
calculated as the horizontal asymptote of the hyperbolic curve
obtained by fitting the injected current values, which were deliv-
ered at different durations (2 pA increments at 100–200–300–500–
800 ms), that were required to evoke an AP for each recorded neu-
ron. The points were fitted with the general hyperbolic equation:
y ¼ P1x=P2 þ x;
where P1 represents the horizontal asymptote.
Spontaneous excitatory postsynaptic currents (sEPSCs)were
recorded in a voltage-clamp configuration (−70 mV holding
potential) using electrodes filled with an intracellular solution
containing (inm): 139.5 cesiummethanesulfonate (CsMeSO3),
1 ethylene glycol bis (β-aminoethyl ether)-N,N,N′,N’-tetraacetic
acid (EGTA), 5.5 CsCl2, 0.1 CaCl2, 10 N-2-hydroxyethylpipera-
zine-N’-2-ethanesulfonic acid (HEPES), 2 MgCl2, and 2 Mg-ATP
(pH 7.3, 300 mOsm). By using ACSF and this internal solution,
the chloride equilibrium potential, which was calculated by
the Nernst equation, was −70 mV. Under these experimental
conditions, the net flux of chloride ions was null, which en-
sured that only glutamatergic excitatory currents were re-
corded. Furthermore, at the holding potential of −70 mV
and using ACSF containing MgCl2, the sEPSCs mediated by
NMDA receptors were nullified. In some experiments, the
AMPA/Kainate antagonist 6-cyano-7-nitroquinoxyline-2,3-
dione (CNQX, 10 μ) was added to the ACSF. In this condition,
all synaptic events were blocked, which indicated that they
were due to the activation of AMPA/Kainate receptors. In
some experiments, the voltage-gated sodium channel blocker
tetrodotoxin (TTX 1 µ, Sigma–Aldrich) was added to the
ACSF in order to record quantal miniature excitatory postsy-
naptic currents (mEPSCs).
After the formation of a high-resistance seal (>1 GΩ), the
capacitance and the resistance of the electrodes were compen-
sated electronically. The signals were amplified using a Multi-
clamp 700B patch-clamp amplifier (Molecular Devices),
sampled at 20 KHz, filtered at 3 KHz, and stored in a computer.
The data were acquired with a Digidata 1400A (Molecular De-
vices). The capacitance and resistance membrane values
were obtained using the Membrane test function of pClamp
10 software (Molecular Devices). Whole-cell access resistances
measured in the voltage-clamp mode were in the range of
5–20 MΩ.
Cell Labelling of Recorded Cells
Immediately after recording, the slices containing biocytin-
loaded cells were fixed by immersion in 4% paraformaldehyde
in 0.1  PBS overnight at 4°C. The slices were collected in PBS,
rinsed 3 times in the same buffer, and then incubated with
Cy2-conjugated Streptavidin (1 : 200; Jackson Immunoresearch
Laboratories) in PBS 0.3% Triton X-100 for 3 h at RT.
After three 5-min washes in PBS, the slices were incubated
overnight at 4°C in PBS containing 1% bovine serum albumin,
1% Triton X-100, and the following primary antibodies: rabbit
anti-VGluT1 (1 : 1000; Synaptic System) and mouse anti-VGluT2
(1 : 1000; Millipore). The slices were then washed 3 times in PBS
and incubated for 2 h at RT with a cocktail of secondary anti-
bodies, including Alexa Fluor 555 donkey anti-rabbit IgG and
Alexa Fluor 647 donkey anti-mouse IgG (Invitrogen). Further-
more, to assess the cytoarchitectonic areas and layers of
the different recorded slices, the latter were counterstained
with NeuroTrace® 640⁄660 deep-red Fluorescent Nissl Stain
(Invitrogen). After additional 3 washes in PBS, the sections were
mounted using an anti-fade medium (Fluoromount; Sigma).
Neurons of interest were identified on 10× objective (Plan-
Apochromat, Zeiss; NA = 0.30) and captured on 40× oil immersion
objective (NA = 1.3; zoom factor 0.5) through a confocal laser-
scanningmicroscope (CLSM700; Zeiss). The following acquisition
settings were used: image format 1024 × 1024; image size 318.8 ×
319.8 μm; Airy units 1.55 producing an optical section thickness
of 1.2 μm; 25 z-stack series with az-spacing 1.25 μm; pixel dwell
time 3.15 μs. To generate projection images, themaximum inten-
sity algorithm of the CLSM software was used. The confocal
image acquisitions were performed so that all samples were cap-
tured using consistent settings for laser power and detector gain.
Although confocal imaging is an indispensable tool for ana-
lysis of neural components at the subcellular and cellular level
of organization, using thick slices of 275-µm confocal imaging
has some limitations that must be taken into account. In these
very thick slices, photobleaching of the fluorophores in focal
planes can be problematic and the collection of a stack of images
from such an extended volume can degrade the signal from dee-
per sections compared with those from the surface. In our study,
in order to reduce photobleaching, we used a low number of
scans (maximum 4) and a low laser power (maximum 7%). Fur-
thermore, to generate the projection image, the first and the
last images of the z-series were discarded, so that only central
images were used. These procedures allowed a better image def-
inition and amore reliable analysis. Finally, the figures were gen-
erated byadjusting only the brightness and the contrast andwere
composed using Adobe Illustrator CS5.
Histology and Immunohistochemistry
The animals were perfused transcardially with 50 mL of saline,
followed by 50 mL of 4% paraformaldehyde under anesthesia,
which was induced by intraperitoneal injections of Rompun
(xylazine, 20 mg/mL, 0.5 mL/kg body weight) and Zoletil (tileta-
mine and zolazepam, 100 mg/mL and 0.5 mL/kg body weight).
Each brainwas removed immediately, post-fixed in the samepar-
aformaldehyde solution for 2 h, and after 3 washes in PBS, it was
transferred to a 30% sucrose solution at 4°C until it sank. The
brains were cut into 6 series of 30-μm-thick transverse sections
using a freezing microtome, and the slices were collected in
PBS. Furthermore, the sections were incubated overnight at 4°C
in PBS containing 0.3% Triton X-100, the following primary anti-
bodies: rabbit anti-VGluT1 (1 : 1000; Synaptic System), guinea pig
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anti-VGluT2 (1 : 1000; Millipore), and mouse anti-SMI32 (1 : 1000;
Covance), and 1% bovine serum albumin to block the unspecific
binding of the antibodies. After 3 washes in PBS, the sections
were incubated for 2 h at RT with a cocktail of secondary anti-
bodies, including Alexa Fluor 555 donkey anti-guinea pig IgG,
Alexa Fluor 405 donkey anti-rabbit IgG, and Alexa Fluor 488 don-
key anti-mouse IgG (1 : 200; Invitrogen).
Furthermore, the sections were counterstained with Neuro-
Trace® 640⁄660 deep-red Fluorescent Nissl Stain (1 : 200; Invitro-
gen). After further washes in PBS, the sections were mounted
using an anti-fade medium (Fluoromount; Sigma) and examined
under a confocal laser-scanning microscope (Zeiss CLSM700).
The specificity of immunohistochemical labeling was con-
firmed by the omission of primary antibodies and the use of nor-
mal serum instead (negative controls).
The cytoarchitectonic areas and layers of the different slices
were further determined in Nissl-stained sections according to
Franklin and Paxinos′ Atlas of Mouse Brain (Franklin and Paxinos
1997) and to Zilles (Zilles 1985). The M1 was defined anteriorly
from 1.18 mm to the bregma to posteriorly −0.34 mm to the breg-
ma, as defined by Franklin and Paxinos (1997).
The relatively narrow Layer IV and thick Layer V defined the
lateral andmedial boundaries ofM1, and ventral boundaries con-
sisted of themost dorsal part of the corpus callosum as previous-
ly described (Oswald et al. 2013).
The area of interest (M1) was identified by using a 10× object-
ive (Plan-Apochromat, Zeiss; NA = 0.30; zoom factor 0.5) and cap-
tured through a confocal laser-scanning microscope (CLSM700;
Zeiss). The following acquisition settings were used: image for-
mat 1024 × 1024; image size 1279.1 × 1279.1 μm; Airy Units 1.37
producing an optical section thickness of 13.2 μm; pixel dwell
time 12.61 μs. The confocal image acquisitions were performed
so that all samples were captured using consistent settings for
laser power and detector gain. Finally, the figures were generated
by adjusting only the brightness and the contrast and were com-
posed using Adobe Illustrator CS5.
Morphological Analysis
Measurements of dendrite arborization were performed in previ-
ously recorded neurons (cell = 16 per group;N = 4 per group) filled
with biocytin. Given that the thickness of slices (275 µm) imposed
by electrophysiological recordings prevented visualization of the
entire dendritic arborization of neurons, the analysis was re-
stricted to the basal dendrite compartment which, having a re-
duced extension, presented only few truncated dendrites. First,
the total length of basal dendrites wasmeasured using an optical
microscope (DMLB, Leica) equipped with amotorized stage and a
camera connected to software (Neurolucida 7.5, MicroBright-
Field) that allowed a quantitative 3D analysis of the entire com-
partment. Then, following the application of a grid with
concentric circles (distance between circles: 25 μm) on the screen
of the monitor, both the length of the dendrite portions within
each ring and the number of intersections with each circle were
measured at an increasing radial distance from the center of the
soma (Sholl analysis) using Neurolucida Explorer software.
Additional groups of previously recorded biocytin-filled neu-
rons (cell = 11 per group; N = 4 per group) were used for spine
density measurements carried out using a Zeiss CLSM700 con-
focal laser-scanning microscope (Zeiss). Neurons of interest
were identified on 10× objective, and spines were captured with
a 63× oil immersion objective (Plan-Apochromat, Zeiss; NA = 1.4)
zoom factor 2.0; image format was 1024 × 1024; image size was
50.8 × 50.8 μm; Airy Units 1 producing an optical section
thickness of 1.3 μm; z-spacing 0.20 μm; number of optical sec-
tions was about 70–80; pixel dwell time 0.79 μs. For each neuron,
three to five 30–100-μm dendritic segments were randomly ac-
quired for spine counts. After image collection, each segment
was analyzed for spine density using the Imaris 7.6.5 (Bitplane
AG) software. Only protrusions with a clear connection of the
head of the spine to the dendrite shaft were counted as spines.
Spine density was then expressed as the number of spines per
10-μm dendrite length. The experimenters were blind to the ex-
perimental group.
Densitometric Analysis of Fluorescence Images
Densitometric analysis of the target proteins, namely VGluT1
and VGluT2, was performed on perfused mouse brain sections.
In order to avoid staining variability among sections and ex-
perimental groups, sections of mouse brains were incubated
with the same cocktail of primary and secondary antibodies at
the same time. Furthermore, confocal settings (described earlier)
for image capture were maintained constant throughout the ac-
quisition of sections from the 3 groups of mice. After confocal ac-
quisition (described earlier), images were exported in TIFF and
analyzed with ImageJ software (http://rsb. info.nih.gov/ij/; Na-
tional Institutes of Health).
The background signal for all antibodies was determined in a
non-stained area. For each channel, the threshold was adjusted
according to the background signal and kept constant between
sections. VGluT1- andVGluT2-associated signalswere quantified
in the layers of interest by manually outlining individual layers
(Layer II/III and V) through overimposing fluorescent Nissl stain-
ing on the VGluT1 or VGluT2 signals. For Layer II/III and Layer V
(deep part), mean signal intensities (F) of VGluT1 and VGluT2
were performed on 2 squared frames (100 μm per side) pseudo-
randomly distributed medio-laterally on the 6 sections, one
every 250 μm, sampled in every mouse to cover the M1 rostro-
caudal extent entirely. The F/A ratio defines mean fluorescence
of individual samples (F) normalized to total cellular surface
(A). Accordingly, quantification was done on 12 samples per
mouse (5 mice per group—total group samples n = 60). Data col-
lecting for densitometry was done by experimenter blind to the
group analyzed.
Tissue Lysate Preparation and Western Blot Analyses
Motor cortex (M1) was isolated under a dissection microscope
using the cingulum, the ventricles, and the corpus callosum as
landmarks from 275-μm-thick coronal slices, prepared as de-
scribed earlier. Slices were placed on a 0.5-mm square grid, the
medial cut was performed on the vertical of the cingulum, and
the lateral cut was approximately 1 mm. Ventral cut followed
the border with the callosum. Afterward, the isolated portion of
M1 was homogenized, and the proteins were extracted in RIPA
buffer (50 m NaCl, 50 m Tris–HCl pH 7.4, 10% glycerol,
320 m sucrose, 1% TX100, plus protease inhibitor cocktail,
1 m Na3VO4, 1 m DTT, and 5 m NaF) for 30 min on ice and
then were centrifuged for 10 min at 4°C (14.000 rpm). The super-
natants were collected, and the protein content was quantified
by Bradford’s colorimetric assay (Bio-Rad). Each protein sample
was separated by SDS–polyacrylamide gel electrophoresis and
transferred to a nitrocellulose membrane. The membranes
were saturated with 5% dried nonfat milk and incubated over-
night with specific primary antibodies, including rabbit anti-
VGluT1 (1 : 10 000; Synaptic System), rabbit anti-VGluT2 (1 : 10
000; Synaptic System), and mouse anti-β-actin (1 : 5000; Sigma).
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The membranes were then incubated with the appropriate
horseradish peroxidase-conjugated secondary antibodies. Immu-
noreactive bands were detected using an enhanced chemilumin-
escence kit (ECL; Amersham Biosciences). The relative levels of
immunoreactivity were determined by densitometry using the
software ImageQuant 5.0. Samples were incubated with the spe-
cific primary antibodies. Densities of protein bands in thewestern
blots were measured, and mean ratios between proteins and β-
actin were reported as percentage of control values.
Quantitative Real-Time PCR
TheM1was isolated from coronal slices as described earlier. RNA
was extracted using TRIzol reagent (Invitrogen). Any remaining
genomic DNA was eliminated with an RNase-Free DNase Set
(Qiagen) according to the manufacturer’s instructions. 1 µg of
total RNAwas used for the RT reaction using the SuperScript VI-
LOTM cDNA Synthesis Kit (Invitrogen). The following real-time
PCR (RT-PCR) program was used: 25°C for 10 min, 42°C for
60 min, and 85°C for 5 min. The expression of the different pri-
mers was assessed by quantitative RT-PCR (qRT-PCR) using a
SensiMixTM SYBR Kit (Bioline) as a fluorescent dye to monitor
cDNA amplification. The following PCR program was used: 95°C
for 10 min, 40 cycles at 95°C for 5 s, and 60°C for 100 s. The primers
used includedmouseVGluT1 F (5′-TTTGAGATCAGCAAGGTGGGG-
3′), mouse VGluT1 R (5′-GTGACGACTGCGCAAAAAGT-3′), mouse
VGluT2 F (5′-ATCATTGTGCCTATCGGGGG-3′), mouse VGluT2 R
(5′-GCCAAAACCCCCACAATTCA-3′), mouse β-actin F (5′-GCTCC
GGCATGTGCAAAG-3′), and mouse β-actin R (5′-CCATCACACCCTG
GTGCCTA-3′). β-Actin was used as the housekeeping gene for
quantity normalization. 1 µl of the first strand of cDNA product
was used for amplification (in triplicate) in 20 µL reaction solution,
which contained 10 µL of iQTM SYBR Green Supermix (Bio-Rad)
and 1 µmol of each primer. The following PCR program was
used: 95°C for 3 min, 40 amplification cycles at 95°C for 10 s, 56°C
for 20 s, and 72°C for 30 s. The fold-changewas determined by the
2−ΔΔCT method.
Statistical Analyses
The analysis of current-clamp recordings was performed off-line
using the software Clampfit 9 (Molecular Devices). The data are
presented as the mean ± standard error (SE), with “n” indicating
the number of analyzed neurons and “N” the number of used an-
imals. Statistically significant differences were determined using
the one-way ANOVA test followed by Bonferroni’s post hoc test
and the unpaired Student’s t-test, when necessary. To analyze
synaptic activity, the 6.0.7 version of Mini Analysis Program
(Synaptosoft, Inc.) was used. sEPSCs and mEPSCs were manually
detected using a 10 pA threshold crossing algorithm. The inter-
event interval (IEI), the event amplitude, the area, and the kinetic
parameters (rise and decay times) were compared between the
control, G93A, and SOD1 mice. The cumulative amplitude and
IEI plots obtained from a single cell in the different neuronal
groups were compared using the Kolmogorov–Smirnov (K–S)
test. Statistical analysis was performed using Origin 7 (Microcal
Software) and SPSS 17.0 forWindows (SPSS, Inc.) software. Differ-
ences in total dendrite lengthwere estimated using the statistical
Student’s t-test. Differences in dendrite length and branch nodes
at increasing distance from the soma were estimated using two-
way ANOVAswith “genotype” asmain factor and “radial distance
from soma” as repeated factor. Students t tests were used for
post hoc comparisons of groups at specific segments, and for
between-group comparisons of spine density. Values of P < 0.05
were considered statistically significant.
Results
Morphological Reconstruction of Layer V Cortical
Pyramidal Motor Neurons by Biocytin Labelling
To validate the neuronal type identified by infrared illumination,
a subset of putative Layer V pyramidal neurons thatwere charac-
terized by the typical repetitive firing of cortico-spinal neurons
(n = 40; control n = 18; G93A n = 18; SOD1 n = 4), localized in the
M1 of the coronal slices, was filled with biocytin to reveal their
morphological features. All recorded neurons filled with biocytin
in fluorescent Nissl-stained slices were located in the deep por-
tion of Layer V of the M1 area (Fig. 1A). Furthermore, all recorded
biocytin-labeled neurons presented classical features of spiny
pyramidal neurons. Specifically, they displayed a triangular-
shaped soma, a large apical dendrite, and multiple basal den-
drites (Fig. 1A′).
G93A Layer V Corticomotor Neurons Show Paroxysmal
Hyperexcitability
The singlemotor neuron excitabilitywas analyzed by performing
whole-cell patch-clamp recordings, in current-clamp mode, in
P26–P31 control, SOD1, and G93Amice. Only neurons that looked
like pyramidal and that responded to a current injection with re-
petitive firing, as reported in Materials and Methods, were con-
sidered for the final analysis. Because there were no significant
differences between control and SOD1 in all the experiments re-
ported in this study, the 2 experimental groups were unified and
denoted as control.
Figure 1. Localization of Layer V pyramidal neurons in the mouse M1. (A)
Schematic and low-magnification pictures showing the localization of recorded
and then biocytin-filled neurons (red square) in a 275-μm coronal section Nissl-
counterstained in the motor cortex (M1) delimited by white lines. (A′) Confocal
microscope image of a biocytin-loaded pyramidal neuron recorded from a
mouse coronal slice. Note the triangular shape of the soma, the large apical
dendrite, and the multiple basal dendrites typical of the pyramidal neurons of
the cerebral cortex. Scale bars in Panel A: 400 μm; in Panel A′: 50 μm.
WM=white matter; I–VI = cortical layers.
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The membrane passive properties were analyzed in the con-
trol (N = 8) and G93A (N = 8) pyramidal neurons. The injection of
currents (500 ms) of different amplitudes from the resting mem-
brane potential, which evoked responses that reached a steady-
state of potentials, was used to calculate themembrane’s passive
properties. In particular, the resting membrane potential (con-
trol: −64.26 ± 0.94 mV, n = 31; G93A: -65.99 ± 1.02 mV, n = 17; P >
0.05 unpaired Student’s t-test), the membrane resistance (con-
trol: 144.27 ± 11.82 MΩ, n = 31; G93A: 182.34 ± 17.16 MΩ, n = 17; P >
0.05 unpaired Student’s t-test), and the τ membrane (control:
19.75 ± 1.21 ms, n = 31; G93A: 23.68 ± 2.68 ms, n = 17; P > 0.05 un-
paired Student’s t-test) were unaffected by mutated human
transgene overexpression (data not shown).
To analyze the neuronal intrinsic excitability, the F–I gain va-
lues were calculated, as described in Materials and Methods. The
AP firings in response to 1-s depolarizing current steps (+20/+100-
pA, 20-pA steps) were recorded under the current-clamp condi-
tion in the control and G93A motor neurons and, for all injected
currents equal to or above +40 pA, the firing frequency in the
G93A neurons was significantly higher compared with the con-
trol neurons (Fig. 2A), confirming previously reported results
(Carunchio et al. 2010). The gain values, calculated for each neu-
ron, were significantly higher in the G93A neurons (0.15 ± 0.01,
n = 17) than the control neurons (0.10 ± 0.01, n = 31; P < 0.01 un-
paired Student’s t-test; Fig. 2B,C).
Finally, the rheobase parameter was calculated as described
in Materials and Methods. In the G93A motor neurons, the cur-
rent amplitude required to evoke an AP was lower compared
with the control neurons (control: 70.20 ± 5.02 pA, n = 31; G93A:
47.24 ± 6.10 pA, n = 17; P < 0.01 unpaired Student’s t-test; Fig. 3),
which confirmed the higher excitability in neurons expressing
mutant SOD1.
G93A Layer V Corticomotor Neurons Show Increased
Frequencies of Spontaneous and Miniature Excitatory
Postsynaptic Currents
To verify the status of excitatory neurotransmission in the G93A
motor neurons, firstly sEPSCs were recorded in acutely prepared
cortical slices from the P26–P31 control (N = 7) and G93A (N = 6)
mice. Layer V pyramidal neurons in the M1 region receive
intercortical excitatory inputs from higher layers (Layer II/III) at
the level of their apical dendrites and intracortical excitatory in-
puts at the level of their multiple basal dendrites (Hooks et al.
2013; Petersen and Crochet 2013; Shepherd 2013). In this work,
whole-cell voltage-clamp recordings were carried out (Vhold =
−70 mV) from Layer V cortical pyramidal neurons using
CsMeSO3-filled patch-pipettes. In these experimental condi-
tions, only spontaneous synaptic currents mediated by AMPA/
Kainate receptors were recorded (see Materials and Methods)
in the control and G93A neurons. The sEPSCs were completely
abolished when CNQX (10 µ) was added to the ACSF, which
confirmed that the synaptic events were mediated by non-
NMDA receptors (Fig. 4A).
The analysis of the sEPSCs demonstrated that themean of the
IEIswas significantly shorter in the G93A comparedwith the con-
trol (Fig. 4B), which indicated that the G93A motor neurons were
characterized by an increased frequency of the sEPSCs compared
with the control (control: 4.52 ± 0.59 Hz, n = 31; G93A: 8.21 ± 1 Hz,
n = 21; P < 0.01, unpaired Student’s t-test; Fig. 4C). Themean amp-
litude of the sEPSCs was not significantly different between the 2
neuronal groups (P > 0.05, unpaired Student’s t-test; Fig. 4D,E).
Furthermore, the analyses of the current kinetics showed that
the rise time (control: 1.96 ± 0.075 ms, n = 31; G93A: 1.95 ± 0.057
ms, n = 21), the decay time (control: 7.79 ± 0.37 ms, n = 31; G93A:
7.39 ± 0.38 ms, n = 21), and the area of sEPSCs (control: 84.90 ± 7.58
pA ×ms, n = 31; G93A: 93.03 ± 8.99 pA ×ms, n = 21) were not differ-
ent between the G93A and control neurons (P > 0.05, unpaired
Student’s t-test; data not shown).
In order to block AP-dependent neurotransmitter release and
to verify whether a general cortical environment alteration oc-
curs, we performed whole-cell recordings of quantal miniature
glutamate events (mEPSCs) in Layer V pyramidal neurons by add-
ing TTX (1 µ) in the bath (Fig. 5). As well as sEPSCs, a higher fre-
quency of the mEPSCs was observed in G93A (3.12 ± 0.35 Hz,
n = 22, N = 9; P < 0.01, unpaired Student’s t-test; Fig. 5B) than that
in control motor neurons (1.78 ± 0.24 Hz, n = 24, N = 11), whereas
no differencewas observed for the events amplitude (P > 0.05, un-
paired Student’s t-test; Fig. 5C), decay time (control: 7.06 ± 0.29
ms, n = 24, N = 11; G93A: 6.05 ± 0.22 ms, n = 22, N = 9; P > 0.05, un-
paired Student’s t-test), and rise time (control: 1.78 ± 0.08 ms, n =
24, N = 11; G93A: 1.64 ± 0.05 ms, n = 22, N = 9; P > 0.05, unpaired
Student’s t-test, data not shown).
G93A Layer V Hyperexcitable Corticomotor Neurons
Show Expanded Dendrite Arborisation without
Variations in the Spine Density
There is evidence that the formation of dendritic arbors is an ac-
tivity-dependent regulated process with size and geometry being
adjusted as a function of the level and the distribution of inputs
received (Tripodi et al. 2008). Thus, the augmentation of single-
cell discharge and EPSC frequency in the G93A mice Layer V
motor neuronsmight strongly affect the dimension and ramifica-
tion of the dendritic arbor in these same neurons. To examine
this point, previously recorded biocytin-filled neurons from
G93A mice and control mice were compared for the extent of
their basal dendrite arborization and the density of spines in
the same dendrite compartment. Results first revealed that
basal dendrites in G93A Layer V motor neurons were globally
longer (P < 0.01, Fig. 6A–C) compared with the control neurons.
Sholl analysis data then revealed that G93A dendrites were long-
er (Fig. 6D) and exhibited more intersections with the concentric
circles (Fig. 6E) compared with the control dendrites at distances
ranging between 50 and 125 μmfrom the center of the soma (den-
dritic length: 50 μm P < 0.05, 100 μm P < 0.01, 125 μm P < 0.05; inter-
sections: 50 μm P < 0.05, 75 μm P < 0.05, 100 μm P < 0.05). However,
the spine density calculated on basal dendrites was not found to
vary between G93A and control mice (P > 0.05; Student’s t test;
Fig. 6F–H).
Vesicular Glutamate Transporter 2 (VGluT2) mRNA and
Protein Levels are Increased in Synaptic Terminals
Surrounding G93A Layer V Corticomotor Neurons
We then investigated whether the increased frequency of EPSCs
observed in theM1 of G93Amicewas influenced by an increase of
glutamate-containing vesicles at the presynaptic level (Moechars
et al. 2006). We investigated the expression level of 2 VGluTs,
namely, the vesicular glutamate transporter 1 (VGluT1) and the
vesicular glutamate transporter 2 (VGluT2), in the control and
G93A mice. In the M1, where Layer IV is almost absent, in both
the control and G93A mice, all layers showed a diffused VGluT1
immunoreactivity (Fig. 7A–H). Densitometric analysis of VGluT1
immunoreactivity (IR) in M1 cortical layers showed that, in
Layer II/III of G93A (F/A = 0.37 ± 0.015), VGluT1 IR was not signifi-
cantly different compared with control (F/A = 0.36 ± 0.016; P > 0.05
paired Student’s t-test). Similarly, in the deep part of Layer V of
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G93A mice (F/A = 0.38 ± 0.018), VGluT1 IR was not significantly
different to control (F/A = 0.36 ± 0.017; P > 0.05 paired Student’s
t-test; data not shown).
Conversely, VGluT2 immunoreactivity in the different layers
of M1 was significantly different between the control and G93A
mice (Fig. 8A–H). In the control mice, only the deep part of Layer
II/III showed a weak VGluT2 immunoreactivity (Fig. 8A–D). In the
G93A mice, VGluT2 immunoreactivity in the M1 was more in-
tense compared with the control (Fig. 8A–H). Specifically, in the
G93A, we found that the deep part of Layer II/III showed a clear
and intense VGluT2 immunoreactivity (Fige 8E). Furthermore,
in the G93A mice, a moderate VGluT2 immunoreactivity, which
was not present in the control (Fig. 8A), was observed in the dee-
per part of Layer V (Fig. 8E). Densitometric analysis of VGluT2 im-
munoreactivity (IR) in M1 cortical layers showed that, in Layer II/
III of G93A (F/A = 0.32 ± 0.015), VGluT2 IR was significantly higher
compared with control (F/A = 0.22 ± 0.016; P < 0.0001 paired Stu-
dent’s t-test). Similarly, in the deep part of Layer V of G93A
mice (F/A = 0.30 ± 0.016), VGluT2 IR was significantly higher
than that in control (F/A = 0.12 ± 0.008; P < 0.0001 paired Student’s
Figure 2. Neuronal hyperexcitability is a feature of G93A cortical motor neurons. (A) Representative repetitive firing in control and G93A neurons evoked by +20, +40, +60,
+80 and +100 pA current injections (1 s) under the current-clamp condition. Thenumberof APs evoked by the same injected currentwas higher in theG93Amotor neurons
comparedwith the control. (B) AP frequencies plotted against the injected current intensities of the representative control and G93A neurons shown inA. The points were
fitted with straight lines, and the slopes represent the gain (F–I) values. (C) Bar plot of the means ± standard errors of the gains in the control (0.10 ± 0.01, n = 31, N = 8) and
G93A (0.15 ± 0.01, n = 17, N = 8) neurons. **P < 0.01 unpaired Student’s t-test.
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t-test; data not shown). As expected, because of the higher dens-
ity of VGluT2 in the presence of a stable density of VGluT1, we ob-
served a decreased VGluT1:VGluT2 ratio of G93A mice compared
with control in both Layers II/III (1.15 vs. 1.63) and V (1.26 vs. 3.0).
To confirm that changes in VGluT2 IR were confined toM1 and
did not affect other cortical areas, we analyzed VGluT2 expression
in the primary somatosensory cortex (S1) of G93A and control
mice. Qualitative and quantitative observations showed that, in
S1, no differences in VGluT2 IR were present between G93A and
control mice (Supplementary Fig. 1). Densitometric quantification
was done on n = 50 samples per group (control N = 5; G93A N = 5).
To better define the distribution of the VGluT1- and VGluT2-
synaptic terminals surrounding Layer V pyramidal neurons, we
performed VGluT1- and VGluT2 immunofluorescence on the
slices of the control and G93A mice that contained the biocytin-
filled neurons (Fig. 9A–D).
We found that, in the control mice, the synaptic terminals lo-
cated over the biocytin-filled pyramidal cells of Layer V predom-
inantly expressed VGluT1 (Fig. 9A), whereas only a few synaptic
terminals expressed VGluT2 (Fig. 9B). In the G93A mice, we ob-
served many more synaptic contacts on the biocytin-filled pyr-
amidal cell of Layer V compared with the control and an almost
equal representation of VGluT1 and VGluT2 terminals (Fig. 9C,D).
Furthermore, to additionally confirm the data on VGluTs, we
performed qRT-PCR (N = 7 per group) and western blotting on
the M1 in the G93A and control mice (N = 6 per group). qRT-PCR
results confirmed the immunohistochemical data. VGluT1
mRNA levels were similar in the G93A and control mice (P > 0.05,
paired Student’s t-test; Fig. 9E). VGluT2 mRNA levels differed
significantly in the G93A compared with the control mice, with
the former presenting more than a 2-fold increment (P < 0.01,
paired Student’s t-test; Fig. 9E). Similarly, the western blot ana-
lysis showed no significant differences in the VGluT1 expression
level between the G93A and control (P > 0.05, paired Student’s
t-test; Fig. 9F), but a large increase in the level of VGluT2 protein
(P < 0.01, paired Student’s t-test; Fig. 9F) in the G93A compared
with the control. These results demonstrate that VGluT2 expres-
sion, as detected by immunohistochemistry, qRT-PCR, and west-
ern blotting, was significantly higher in the G93A than that in
control mice.
Discussion
This study provides evidence of alterations in the functional and
structural properties of G93A corticomotor neurons and an ab-
normal glutamatergic activity in their immediate environment.
The functional alterations consisted of significantly lower rheo-
base values of singlemotor neurons, associated with a frequency
augmentation of the sEPSCs andmEPSCs. In ALS patients, a lower
rheobase value of motor axons has already been observed
(Mogyoros et al. 1996; Mogyoros et al. 1998). Neuronal hyperexcit-
ability has been previously reported in different central nervous
Figure 3. The rheobase in G93Awas significantly lower comparedwith the controlmotor neurons. (A) Representative traces of current injections (100 and 300 ms) required
to evoke anAP in representative control andG93Aneurons. (B) Hyperbolic curves obtained by fitting the amplitude of the injected currents required to evoke anAP, plotted
against the duration of the electrical stimulations. (C) Bar plot of themeans ± standard errors of the rheobase values in the control (70.20 ± 5.02 pA, n = 31, N = 8) and G93A
(47.24 ± 6.10 pA, n = 17, N = 8) neurons. **P < 0.01 unpaired Student’s t-test.
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system areas of ALS mouse models (Pieri et al. 2003; Kuo et al.
2005; van Zundert et al. 2008; Pieri et al. 2009; Carunchio et al.
2010; Nieto-Gonzalez et al. 2010; Thielsen et al. 2013) and ascribed
to a reduction of the recovery time from the transient sodium
current inactivation (Zona et al. 2006) and/or an upregulation of
persistent inward sodium current (INap) (Kuo et al. 2005; Pieri
et al. 2009; Carunchio et al. 2010). Interestingly, INap, which con-
trols the threshold of neuronal excitability (Boehmer et al. 2000;
Do and Bean 2003; Levin et al. 2006), is blocked by low doses of
riluzole (Kuo et al. 2005; Pieri et al. 2009; Schuster et al. 2012).
This drug, which is one of the most commonly used drugs in
the treatment of ALS (Gordon 2011; Miller et al. 2012; Vucic, Lin
et al. 2013), has also been reported to exert its neuroprotective
effect by inhibiting the glutamatergic transmission, either at
presynaptic level or postsynaptically (Frizzo et al. 2004; Wang
et al. 2004; Cheah et al. 2010). The multiple effects of Riluzole,
which all point to neuronal excitability reduction (Bellingham
2011), may explain its beneficial influence observed in the clinic,
unlike anti-NMDA agents that have been reported to have no
similar therapeutic effects (Pamphlett et al. 2003; de Carvalho
et al. 2010). The higher EPSC frequency in the motor cortex,
here firstly reported, is in line with the higher expression of
N-type voltage-dependent calcium channels that was previously
reported in G93A cultured cortical neurons (Pieri et al. 2013).
These channels, together with P/Q-type calcium channels,
preferentially interact with the release machinery in several
central synapses with the consequence of triggering neurotrans-
mitter release (Mintz et al. 1995; Qian and Noebels 2001; Cepeda
Figure 4. The G93A motor neurons show a significantly increased sEPSC frequency compared with the control. (A) Representative traces of sEPSCs in a control (left) and
G93A (right) neuron. In the presence of CNQX (10 µ, Sigma), a non-NMDA receptor antagonist, the synaptic events were completely abolished in both neuronal
populations. (B) Cumulative probability plots of IEIs of sEPSCs in the control and G93A neurons shown in A. In the G93A motor neuron, the IEI was significantly lower
compared with the control neuron (P < 0.01; K–S test). (C) Bar plot of the sEPSC frequency means and standard errors in the control and G93A neurons. (D) Cumulative
amplitude distributions of the control and G93A sEPSCs shown in A (P > 0.05; K–S test). (E) Bar plot of the means and standard errors of the sEPSC amplitudes in the
control (17.95 ± 1.03 pA, n = 31) and G93A (20.42 ± 1.68 pA, n = 21; P > 0.05 unpaired Student’s t-test) neurons. **P < 0.01 unpaired Student’s t-test.
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et al. 2004). Nevertheless, virtually nothing is known on how
hyperexcitability impacts cortical glutamatergic transmission,
including neurotransmitter release and vesicular glutamate
packaging.
The higher frequency of EPSCs in G93A pyramidal motor neu-
rons indicates an increase in glutamate release at the presynaptic
level. The higher sEPSCs frequency observed in the ALS mouse
model was not associated with significant differences of ampli-
tude and kinetic properties, rise time, and decay time, which
largely depend on the postsynaptic features of the recorded neu-
rons. Furthermore, the facilitation of glutamate release in the
G93A mice was independent of AP generation in the presynaptic
neuronal terminals, since in G93A pyramidal motor neurons, the
frequency of mEPSCs was still significantly higher than that in
control. This indicates that the increased release of glutamate
has only a synaptic origin.
The presynaptic glutamate release is finely regulated by
VGluTs responsible for packaging glutamate into synaptic vesi-
cles (Fremeau, Kam et al. 2004; Takamori 2006). VGluTs levels,
which are critical for the balance between excitation and inhib-
ition (Cline 2005; Erickson et al. 2006; Seal et al. 2008) and synaptic
transmission (Wojcik et al. 2004; Fremeau, Voglmaier et al. 2004;
Wilson et al. 2005), are altered in different pathological condi-
tions. In fact, previous studies have reported that VGluTs expres-
sion levels are altered in pathologies such as depression
(Moutsimilli et al. 2005; Tordera et al. 2005; Moutsimilli et al.
2008), schizophrenia (Eastwood and Harrison 2005; Uezato et al.
2009), Alzheimer’s disease (Kirvell et al. 2006), and Parkinson’s
disease (Kashani et al. 2007). Moreover, the importance of the
VGluT2 expression level has been reported in VGluT2 knockout
mice, inwhich the total gene deletion induced perinatal lethality,
whereas the heterozygous gene condition led to glutamatergic
signaling deficit in the thalamus (Moechars et al. 2006). However,
little is known about the role of VGluTs in the pathophysiology
of ALS. Recently, it has been demonstrated that the genetic
reduction of VGluT2 protein levels in G93A mice reduced motor
neuron degeneration in the lumbar spinal cord of symptomatic
mice but was ineffective in delaying the disease onset or increas-
ing the life span, probably because too few motor neurons were
rescued to affect disease progression (Wootz et al. 2010).
In this study, we showed for the first time that VGluT2 mRNA
and protein levels were significantly enhanced in the M1 region
of G93A mice, whereas VGluT1 levels were unaffected. Our im-
munohistological data then revealed that VGluT2 levels were in-
creased only in M1 selective cortical layers, namely, Layers II/III
and deep part of Layer V. Because VGluTs control the amount
and probability of glutamate release (Fremeau, Voglmaier et al.
2004; Wilson et al. 2005; Takamori 2006), increased VGluT2 ex-
pression in Layers II–III and V of the G93A motor cortex is there-
fore consistent with the enhanced frequency of EPSCs of G93A
corticomotor neurons lying in Layer V, although it is not possible
to exclude an increased vesicular turnover. Furthermore, VGluT1
andVGluT2 are present at synapses located in different regions of
the brain. VGluT1 pertains to cortical synapses, whereas VGluT2
is predominately present at thalamic synapses (Fremeau et al.
2001; Fujiyama et al. 2001). Thus, if VGluT1 and VGluT2 immu-
noreactivity can differentiate between synapses of cortical or
thalamic origin (Fujiyama et al. 2001; Barroso-Chinea et al.
2007; Graziano et al. 2008; Hooks et al. 2013), an increase in
VGluT2 should be expected to occur at thalamic synapses. How-
ever, our RT-PCR data question this prediction. In fact, consider-
ing that VGluTs mRNA is expressed in cell bodies and VGluTs
proteins are expressed in axon terminals (Agis-Balboa et al.
2006), an enhancement of VGluT2 mRNA in the M1 region can
suggest an enhanced intracortical transcriptional activity driving
the increment of VGluT2 at theM1 synapses. However, since neu-
rons expressing VGluT2 mRNA are a small minority of M1 neu-
rons, we cannot exclude the fact that the observed increase of
VGluT2 expression is the result of a combination of both intracor-
tical and extracortical synaptic upregulation.
Figure 5.Recordings ofmEPSCs in pyramidal neurons from theM1. (A) Representative traces ofmEPSCs recorded in the control andG93Aneurons. (B) Bar plot of themEPSC
frequencymeans and standard errors in the control and G93A neurons. (C) Bar plot of themeans and standard errors of themEPSC amplitudes in the control (16.15 ± 0.52
pA, n = 24) and G93A (17.61 ± 0.59 pA, n = 22; P > 0.05 unpaired Student’s t-test) neurons. **P < 0.01 unpaired Student’s t-test.
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Immunohistochemical and biochemical data need some con-
sideration. To attempt quantification, it is always a risky busi-
ness, and all techniques present limitations related to the
tissue, antibodies, andfluorescence probes, and to the difficulties
in delimiting areas of interest. To improve the significance of
quantitative evaluations, we adopted 2 methods: immunohisto-
chemistry and biochemistry. The first method provides high pre-
cision in anatomical definition but is somewhat questionable in
Figure 6. Representative images of 3D-reconstructed neurons of Layer Vmotor cortex in the control (A) and G93A (B) mice. (C) Histogram showing basal dendritic length of
biocytin-filled neurons of deepportion of Layer V inM1of control andG93Amice. InG93Amice, LayerVpyramidal neurons showagreater basal dendritic length compared
with control (**P < 0.01; paired Student’s t-test). (D,E) Graphs of Sholl analysis for Layer V pyramidal neuron basal dendritic length and number of intersections per 25-μm
radial unit distance from the soma in the control and G93Amice. G93Amice present an increase in branching complexity at a radial distance of 50–125 μm relative to the
soma (dendritic length: 50 μm P < 0.05, 100 μm P < 0.01, 125 μm P < 0.05; intersections: 50 μm P < 0.05, 75 μm P < 0.05, 100 μm P < 0.05). *P < 0.05; **P < 0.01; Student’s t-test. (F)
Histogram showing themean spine density of pyramidal biocytin-filled neurons in control andG93Amice. Note that spine density of pyramidal biocytin-filled neurons of
G93A and control mice is not significantly different (P > 0.05; Student’s t-test). (G,H) Volume rendering of the maximum projection image created by Filament Tracer
module of Imaris software package for spine density of Layer V pyramidal biocytin-filled neurons in control (G) and G93A (H) mice. Scale bars A,B = 50 μm; G,H = 5 μm.
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Figure 7. Distribution of VGluT1 in the different motor cortex (M1) layers of the control and G93Amice. Confocal images of triple immunofluorescence for VGluT1 (blue),
SMI-32 (green), andNeurotrace (Nissl-fluorescent stain; gray) andmerge in the control (A–D) andG93A (E–H)mice. Note thewidespreadVGluT1 immunoreactivity in allM1
layers of the control (A) and G93A mice (E). cg = cingulum. Scale bar (A–H) = 200 μm.
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Figure 8. Distribution of VGluT2 in the different motor cortex (M1) layers of the control and G93A mice. Confocal images of triple immunofluorescence for VGluT2 (red),
SMI-32 (green), and Neurotrace (Nissl-fluorescent stain; gray) andmerge in the control (A–D) and G93A (E–H) mice. Note that VGluT2 immunoreactivity in theM1 presents
significant differences between the 2 experimental groups. In the control, VGluT2 immunoreactivity is weak in almost all layers except in the deep portion of layers II/III
(A). In theG93Amice, VGluT2 immunoreactivity ismore intense comparedwith the control in almost all layers ofM1 (E). In particular, in theG93Amice, the deepportion of
Layers II/III andVof theM1,which appear densely SMI-32 labeled (F–H), showed amore intenseVGluT2 immunoreactivity comparedwith the control. cg = cingulum. Scale
bar (A–H) = 200 μm.
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sensitivity. On the other hand, the second method may be ques-
tioned regarding precision in anatomical localization but is con-
sidered quite reliable regarding quantification. In our study, both
methods presented convergent results, thus providing quite
compelling evidence of the characteristic pattern of VGluT2 ex-
pression in M1 of G93A mice.
In line with data that showed that the complexity of dendritic
arborization is regulated by neuronal activity and trophic factors
during the course of development (Libersat and Duch 2004;
Tripodi et al. 2008) and that the number of synaptic inputs is
strictly related to the extension of dendritic arborization (Harris
et al. 2003), hyperexcitable neurons exhibited morphological al-
terations in the direction of a structural gain of function. In par-
ticular, although our results indicate that the spine density was
not modified in the mutated neurons compared with control,
we observed that the basal dendrites of Layer V motor neurons,
receiving excitatory inputs from local sources from the same
and/or adjacent areas (Hooks et al. 2013; Petersen and Crochet
2013; Shepherd 2013), were longer and exhibited more ramifica-
tions, indicating an enhanced cortical connectivity in the early
stage of the disease. Some previous reports have shown that den-
drite arborization is increased in the lumbar motor neurons of
G93A mice early (P4–P9) in development (Amendola and Dur-
and 2008), whereas others have shown that it is decreased in
cortical motor neurons of older (3 months) G93A mice (Spalloni
et al. 2010). Our pattern of results is therefore consistent with a
scenario in which the early detected enhancement of neuronal
activity in motor neurons might initially trigger an increase of
connectivity in G93A motor circuits. Then, the parallel activa-
tion of glutamate release, revealed by the enhancement of the
VGluT2 level, detected in the very presymptomatic mouse
age, would increase excitotoxicity in themotor neuron environ-
ment and then produce the opposite structural alterations,
starting from a reduction of dendrite arborization in older
mice (Spalloni et al. 2010) until neuronal loss (Seijffers et al.
2014).
It is therefore evident that the exacerbated dendritic arbori-
zation, the increased expression of VGluT2, and the hyperexcit-
ability in the M1 Layer V neurons, all events observed at a very
early stage of the disease, represent concomitant factors highly
favorable to the enhancement of glutamate release, inducing
its accumulation in the M1 region and, consequently, causing
the excitotoxic neuronal death (Kim et al. 2012). In fact, as a con-
sequence of all that has been reported, the greater glutamate
release may lead to higher glutamate levels at the synaptic
clefts, further exacerbated by the decreased levels of glial exci-
tatory amino acid transporter-2 (EAAT2/GLT-1), previously ob-
served both in the motor cortex and spinal cord from ALS
patients (Rothstein 1995; Lin et al. 1998) and confirmed in ALS
mouse models (Bruijn et al. 1997; Rothstein et al. 2005; Foran
and Trotti 2009; Foran et al. 2011; Morel et al. 2013). In alterna-
tive, the decreased EAAT2/GLT-1 expression reported in ALS
may cause higher levels of synaptic glutamate, with a conse-
quent increase of EPSC frequency and upregulation of VGluT2
expression.
Our findings demonstrate for the first time the existence of
early profound alterations in glutamatergic neurotransmission,
associated with modified VGluT2 expression and neuronal
morphology in the ALS motor cortex. These alterations indicate
that the cortical area has a fundamental role in ALS disease
onset and progression and should thus be taken into account
for the treatment of this neurodegenerative disease.
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Supplementary material can be found at: http://www.cercor.
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Figure 9. Immunohistochemical characterization and mRNA/protein expression
of VGluT1 and VGluT2 in the motor cortex (M1) of the control and G93A
biocytin-filled slices. (A–D) Confocal images of triple immunostaining showing
biocytin-filled pyramidal cells of Layer V (green) surrounded by terminals
immunoreactive for VGluT1 (blue) and VGluT2 (red) in the control (A,B) and
G93A (C,D) mice. Note that VGluT1 is expressed by almost all synaptic terminals
both in the control (A) and G93A (C) mice. Conversely, VGluT2 is expressed by few
synaptic terminals in the control (B) and by a large number in the G93A mice (D).
(E) Densitometric graphs of the VGluT1 andVGluT2mRNAexpression normalized
to the internal control (ß-actin), in the control andG93A groups. (F) Representative
immunoblots and densitometric graphs of VGluT1 and VGluT2 protein
expression, normalized to the internal control (ß-actin), in the control and G93A
groups. Note that the levels of VGluT1 mRNA and protein are not significantly
different between the control and G93A groups. Conversely, the levels of
VGluT2 mRNA and protein are significantly higher in the G93A mice compared
with the control. *P < 0.05; **P < 0.01 paired Student’s t-test. Scale bar (A–D) = 25 μm.
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